{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:19Z","timestamp":1794565519863,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jchromb.2026.125311","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:35:05Z","timestamp":1790688905000},"page":"125311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An LC-MS\/MS assay for quantification of plasma biomarkers to assess transporter-mediated drug-drug interactions and biomarker baselines in healthy volunteers"],"prefix":"10.1016","volume":"1285","author":[{"given":"Nikoleta","family":"Palioudaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Aabjerg","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Krogh","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tue Bj\u00f8rn","family":"S\u00f8eborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoline Juul","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2026.125311_bb0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jchromb.2026.125311_bb0010","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.1098","article-title":"Influence of transporter polymorphisms on drug disposition and response: a perspective from the International Transporter Consortium","volume":"104","author":"Yee","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0015","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cpt.1115","article-title":"Disease-associated changes in drug transporters may impact the pharmacokinetics and\/or toxicity of drugs: a white paper from the International Transporter Consortium","volume":"104","author":"Evers","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0020","unstructured":"Drug Interaction Studies M12. ICH Harmonised Guideline, (2024)."},{"key":"10.1016\/j.jchromb.2026.125311_bb0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jcph.6183","article-title":"Clinical assessment of drug transporter inhibition using biomarkers: review of the literature (2015\u20132024)","volume":"65","author":"Rodrigues","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.125311_bb0030","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/cpt.3062","article-title":"Utilization of OATP1B biomarker coproporphyrin-I to guide drug-drug interaction risk assessment: evaluation by the pharmaceutical industry","volume":"114","author":"Kikuchi","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40262-024-01385-0","article-title":"Utilising endogenous biomarkers in drug development to streamline the assessment of drug-drug interactions mediated by renal transporters: a pharmaceutical industry perspective","volume":"63","author":"Choi","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2026.125311_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113202","article-title":"Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry","volume":"184","author":"Suzuki","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.125311_bb0045","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/cpt.2829","article-title":"Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs","volume":"113","author":"Lin","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cpt.2672","article-title":"Coproporphyrin I as an endogenous biomarker to detect reduced OATP1B activity and shift in elimination route in chronic kidney disease","volume":"112","author":"Takita","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.117797","article-title":"Evolution of LC-MS\/MS in clinical laboratories","volume":"555","author":"Yu","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2026.125311_bb0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpba.2016.06.017","article-title":"Quantitative analysis of endogenous compounds","volume":"128","author":"Thakare","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.125311_bb0065","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/cpt.2429","article-title":"Performance of plasma coproporphyrin I and III as OATP1B1 biomarkers in humans","volume":"110","author":"Neuvonen","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0070","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1124\/dmd.122.001012","article-title":"The role of coproporphyrins as endogenous biomarkers for organic anion transporting polypeptide 1B inhibition-progress from 2016 to 2023","volume":"51","author":"Lai","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2026.125311_bb0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/jpet.118.252643","article-title":"Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects","volume":"368","author":"Shen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0080","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00228-014-1770-2","article-title":"N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction","volume":"71","author":"Muller","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.125311_bb0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/cpt.2022","article-title":"Identification of appropriate endogenous biomarker for risk assessment of multidrug and toxin extrusion protein-mediated drug-drug interactions in healthy volunteers","volume":"109","author":"Miyake","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0090","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1124\/dmd.119.087262","article-title":"Elucidation of N (1)-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters","volume":"47","author":"Miyake","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2026.125311_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4155\/bio-2023-0197","article-title":"Inception and development of a LC-MS\/MS assay for the multiplexed quantitation of nine human drug transporter biomarkers","volume":"16","author":"Kadar","year":"2024","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125311_bb0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4155\/bio-2022-0023","article-title":"Development and implementation of urinary transporter biomarkers to facilitate assessment of drug-drug interaction","volume":"14","author":"Luo","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125311_bb0105","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4155\/bio-2017-0272","article-title":"LC-MS\/MS assay for N(1)-methylnicotinamide in humans, an endogenous probe for renal transporters","volume":"10","author":"Luo","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125311_bb0110","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.4155\/bio-2021-0110","article-title":"A novel hydrophilic interaction chromatography assay characterization of 4-pyridoxic acid, an emergent renal organic anion transporter 1\/3 transporter biomarker","volume":"13","author":"Towner","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125311_bb0115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4155\/bio-2017-0270","article-title":"A fully automated and validated human plasma LC-MS\/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III","volume":"10","author":"King-Ahmad","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125311_bb0120","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4155\/bio-2017-0181","article-title":"A highly selective and sensitive LC-MS\/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers","volume":"9","author":"Ramanathan","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125311_bb0125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4155\/bio-2017-0246","article-title":"UHPLC-MS\/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions","volume":"10","author":"Kandoussi","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125311_bb0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jchromb.2017.12.008","article-title":"Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions","volume":"1073","author":"Njumbe Ediage","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2026.125311_bb0135","unstructured":"M.S. Lee, WILEY SERIES ON PHARMACEUTICAL SCIENCE AND BIOTECHNOLOGY: PRACTICES, APPLICATIONS, AND METHODS Series Editor. , 2019."},{"key":"10.1016\/j.jchromb.2026.125311_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465060","article-title":"Solving the retention time repeatability problem of hydrophilic interaction liquid chromatography","volume":"1730","author":"Serafimov","year":"2024","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2026.125311_bb0145","series-title":"Bioanalytical Method Validation for Biomarkers","year":"2026"},{"key":"10.1016\/j.jchromb.2026.125311_bb0150","series-title":"Bioanalytical Method Validation and Study Sample Analysis M10","year":"2022"},{"key":"10.1016\/j.jchromb.2026.125311_bb0155","series-title":"Solubility of Buffers in Aqueous-Organic Eluents for Reversed-Phase Liquid Chromatography","author":"Schellinger","year":"2004"},{"key":"10.1016\/j.jchromb.2026.125311_bb0160","unstructured":"J.J.K. L.R. Snyder, J.W. Dolan, INTRODUCTION TO MODERN LIQUID CHROMATOGRAPHY Third Edition, n.d."},{"key":"10.1016\/j.jchromb.2026.125311_bb0165","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/psp4.70005","article-title":"Pyridoxic acid as endogenous biomarker of renal organic anion transporter activity: population variability and mechanistic modeling to predict drug-drug interactions","volume":"14","author":"Thakur","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.125311_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15020080","article-title":"Is N1-Methylnicotinamide a good organic cation transporter 2 (OCT2) biomarker?","volume":"15","author":"Ailabouni","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.jchromb.2026.125311_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103776","article-title":"Evaluating the utility of endogenous OCT2 and MATE1\/2-K biomarkers for DDI assessment in early clinical settings","volume":"114","author":"Nishii","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2026.125311_bb0180","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cpt.3727","volume":"118","author":"Asano","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125311_bb0185","first-page":"137","article-title":"PBPK model of coproporphyrin I: evaluation of the impact of SLCO1B1 genotype, ethnicity, and sex on its inter-individual variability","volume":"10","author":"Takita","year":"2021","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10.1016\/j.jchromb.2026.125311_bb0190","doi-asserted-by":"crossref","first-page":"957S","DOI":"10.3945\/jn.112.173021","article-title":"Dietary supplement use and smoking are important correlates of biomarkers of water-soluble vitamin status after adjusting for sociodemographic and lifestyle variables in a representative sample of U.S. adults","volume":"143","author":"Pfeiffer","year":"2013","journal-title":"J. Nutr."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226004009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226004009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:50:42Z","timestamp":1794563442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226004009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":38,"alternative-id":["S1570023226004009"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125311","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An LC-MS\/MS assay for quantification of plasma biomarkers to assess transporter-mediated drug-drug interactions and biomarker baselines in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125311"}}